A software program clinically validated to reduce symptoms of major depression looks nothing like a typical mental health app, even though both might display similar mood-tracking screens. The difference lies entirely in what stands behind the interface: clinical trial evidence, defined therapeutic intent, and often regulatory oversight. That distinction defines every application on this list.
Application 1: Mental Health
Digital therapeutics for depression and anxiety typically deliver structured cognitive behavioral therapy protocols through guided modules, exercises, and symptom tracking. These programs are designed to replicate evidence-based therapeutic techniques in a software format, often as a supplement to or extension of traditional therapy rather than a full replacement.
Application 2: Substance Use Disorders
Several digital therapeutics have received regulatory clearance specifically for substance use disorder treatment, delivering structured behavioral interventions and recovery support tools. These products typically integrate with existing addiction treatment programs rather than functioning as standalone care.
Application 3: Chronic Disease Management
Diabetes and hypertension management represent significant digital therapeutic categories, focused on behavior change support, medication adherence tracking, and structured self-management education. These programs often work alongside traditional medical treatment rather than replacing medication or clinical monitoring.
Application 4: Insomnia and Sleep Disorders
Digital therapeutics for insomnia typically deliver cognitive behavioral therapy for insomnia, a well-established evidence-based treatment approach, through structured software programs. This category has produced some of the strongest clinical evidence in the digital therapeutics space, given how well the underlying therapy translates into a guided digital format.
Application 5: Neurological Conditions
Digital therapeutics targeting neurological conditions include products designed to support attention and cognitive function, with at least one product receiving regulatory clearance specifically for pediatric attention difficulties. These applications typically combine game-like engagement mechanics with underlying cognitive training protocols.
Application 6: Pain Management
Digital behavioral approaches to pain management focus on cognitive and behavioral techniques for managing chronic pain, rather than directly treating the underlying physical cause. Evidence in this category continues to develop, and these tools are generally positioned as a complement to, not a replacement for, medical pain management.
Application 7: Cardiovascular Risk Management
Digital therapeutics addressing cardiovascular risk typically focus on behavior modification, including diet, exercise, and medication adherence support, alongside monitoring tools that track relevant metrics over time. These programs often integrate with connected devices to incorporate objective data alongside self-reported information.
Application 8: Respiratory Disease
Chronic respiratory conditions, including asthma and COPD, have digital therapeutic applications centered on self-management education, symptom tracking, and adherence support for prescribed treatment regimens. Early detection of worsening symptoms through structured tracking represents a key value proposition in this category.
Application 9: Pediatric and Adolescent Behavioral Health
Digital therapeutics designed for children and adolescents require particular attention to age-appropriate evidence and safeguards, given the added complexity of developmental considerations and parental involvement in treatment. This category has grown carefully, with regulatory clearance processes accounting for these additional considerations.
Application 10: Rehabilitation and Recovery
Digital therapeutics supporting physical rehabilitation typically guide patients through prescribed exercise programs with adherence tracking and progress measurement, often incorporating gamification elements shown to improve consistency compared to traditional printed exercise instructions.
How to Judge Whether a DTx Application Is Clinically Credible
| Credibility Factor | What to Look For |
|---|---|
| Clinical trial evidence | Published, peer-reviewed outcome data |
| Regulatory status | Clearance or approval where applicable |
| Adherence data | Real-world usage evidence, not just trial results |
| Transparency | Clear disclosure of evidence limitations |
A digital therapeutic that cannot point to specific clinical evidence, or that relies on vague testimonial language rather than published outcome data, warrants more skepticism than one with transparent trial results and appropriate regulatory context.
Real Examples Versus Marketing Claims
| Evidence Category | Description |
|---|---|
| Strong evidence | Peer-reviewed randomized trials, regulatory clearance |
| Moderate evidence | Smaller studies, promising but limited data |
| Marketing claims only | Testimonials or vague “clinically studied” language without specifics |
Insomnia and substance use disorder digital therapeutics tend to sit toward the stronger end of this spectrum, given how directly their underlying therapeutic protocols translate from established in-person treatment. Newer categories, including some pain management applications, often sit further along the developing evidence spectrum, worth watching rather than treating as fully established.
Why Adherence Determines Real-World Success
Clinical trial results for digital therapeutics are typically generated under closely supervised conditions, with participants often receiving reminders, check-ins, and structured encouragement that do not exist once a product reaches the general market. Real-world adherence, meaning how consistently patients actually use a digital therapeutic outside a research setting, frequently falls well short of trial-level engagement, and this gap represents one of the category’s most persistent practical challenges.
Products that build in ongoing clinical touchpoints, rather than functioning as a fully self-directed experience, tend to show better real-world adherence than those relying entirely on patient self-motivation. This is one reason many successful digital therapeutics operate within a broader care relationship, with a clinician periodically reviewing progress data, rather than being deployed as a standalone app a patient is simply handed and left to use independently.
What Payers Look For Before Covering a Digital Therapeutic
Insurance coverage decisions for digital therapeutics increasingly hinge on real-world outcome data rather than clinical trial results alone, given the adherence gap described above. Payers typically want evidence that a product reduces downstream healthcare costs, whether through fewer emergency visits, reduced medication needs, or improved management of a chronic condition, before committing to broad coverage. This evidence bar has proven a significant hurdle for many digital therapeutics companies, contributing to the reimbursement uncertainty that continues to shape the category’s business models.
Employers have emerged as an alternative funding path for some digital therapeutics, particularly in mental health and chronic disease categories, sponsoring access for employees as part of broader workplace wellness benefits rather than waiting for traditional insurance coverage decisions. This channel has provided a meaningful revenue path for several companies while the more traditional payer reimbursement landscape continues to mature around the category’s growing but still developing evidence base.
FAQ
Q: What are examples of digital therapeutics?
A: Examples include cognitive behavioral therapy programs for insomnia and depression, substance use disorder recovery support tools, and cognitive training applications for attention difficulties.
Q: What conditions can digital therapeutics treat?
A: Common conditions include depression, anxiety, insomnia, substance use disorder, ADHD, chronic pain, and support for chronic diseases such as diabetes and hypertension.
Q: Are digital therapeutics clinically proven?
A: Evidence varies by product and condition. Categories such as insomnia and substance use disorder tend to have stronger clinical trial support than some newer or less established application areas.
Q: How are DTx products regulated?
A: Some digital therapeutics are regulated as medical devices requiring clearance before marketing, while regulatory pathways and requirements vary depending on the specific claims and risk level involved.
Q: Are digital therapeutics the same as health apps?
A: No, digital therapeutics require clinical evidence of therapeutic effect for a specific condition, while general health apps typically lack this evidence requirement and focus on wellness rather than treatment.
Q: Can digital therapeutics replace medication?
A: Most digital therapeutics are designed to complement, not replace, traditional medical treatment, though some behavioral health applications can serve as a primary intervention for certain conditions under clinical guidance.